Dr Sloan has been involved in academic research and the biopharmaceutical industry for more than 30 years and brings extensive experience in gastroenterology and inflammatory bowel disease (IBD). At Abivax, Sloan will play a central role in the execution and successful completion of the ongoing global Phase 3 clinical programme with obefazimod for the treatment of ulcerative colitis (CU), as well as subsequent global regulatory submissions and preparations for market launch. He will also manage future clinical development programmes with obefazimod in Crohn's disease. Sloan has held various leadership positions at J&J for 15 years. Most recently, he led the Etrasimod UC programme first at Arena Pharmaceuticals and then at Pfizer.

Abivax develops therapies that modulate the body's immune system to treat patients with chronic inflammatory diseases. The company is based in Paris and Montpellier. Sloan will operate in the US and establish a corporate presence on the US East Coast.